title: Cataract associated with high-dose hematopoietic colony stimulating factor, case report and literature review.
abstract: Granulocyte-colony stimulating factor (G-CSF) is a lineage-restricted hematopoietic growth factor. It induces proliferation and maturation of neutrophilic precursors and progenitors and activates neutrophil functions. It is used to ameliorate or prevent profound neutropenia and its consequences. G-CSF therapy in neutropenic disorders increases neutrophil count and improves infectious complications. However, it is not without side effects. Here, we discuss the case of a 2 years old patient with Kostmann's disease who developed cataracts following high-dose G-CSF therapy. We also review the relevant literature on G-CSF-related complications.
authors: Haematology Department, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
authors: Soad K
authors: SK
authors: Aljaouni
authors: Hanadi M
authors: HM
authors: Aljedani
keywords: Cataract; Congenital neutropenia; G-CSF; Kostmann’s disease; Side effects of G-CSF therapy
references: Br J Haematol. 1995 Sep;91(1):43-5
references: 7577650
references: Coll Antropol. 2001;25 Suppl:145-8
references: 11817006
references: Annu Rev Med. 1990;41:483-96
references: 2184746
references: Cell. 1987 Nov 20;51(4):675-86
references: 3499986
references: Blood. 2006 Jun 15;107(12):4628-35
references: 16497969
references: Blood. 2000 Jul 15;96(2):429-36
references: 10887102
references: N Engl J Med. 1989 Jun 15;320(24):1574-80
references: 2471075
references: Eur J Clin Microbiol Infect Dis. 2004 Jul;23(7):550-9
references: 15232720
references: Lancet. 1988 Mar 26;1(8587):667-72
references: 2895212
references: Am J Hematol. 2003 Feb;72(2):82-93
references: 12555210
references: Acta Paediatr Suppl. 1956 Feb;45(Suppl 105):1-78
references: 13326376
references: Ann Intern Med. 1966 Feb;64(2):328-40
references: 5216294
references: Br J Haematol. 1995 Sep;91(1):150-3
references: 7577623
references: Br J Haematol. 2003 Feb;120(4):685-90
references: 12588357
references: Eur J Cancer. 1993;29A(3):319-24
references: 7691119
references: N Engl J Med. 1989 Jan 5;320(1):38-42
references: 2462670
references: Blood. 1993 May 15;81(10):2496-502
references: 8490166
references: Nat Genet. 2007 Jan;39(1):86-92
references: 17187068
references: Stem Cells. 1997;15 Suppl 1:113-9; discussion 120
references: 9368331
references: Br J Haematol. 1994 Dec;88(4):723-30
references: 7529539
references: Turk J Haematol. 1999 Dec 5;16(4):171-5
references: 27265590
references: J Pediatr. 1995 Feb;126(2):263-5
references: 7531241
references: Trends Pharmacol Sci. 1990 Jul;11(7):285-9
references: 2202141
references: Hematol Oncol Clin North Am. 2004 Dec;18(6):1439-58, x
references: 15511624
references: Surv Ophthalmol. 1986 Sep-Oct;31(2):102-10
references: 3541262
references: Radiother Oncol. 1987 Jun;9(2):131-5
references: 3303161
references: Support Cancer Ther. 2006 Jul 1;3(4):220-31
references: 18632498
references: AIDS. 2000 Jun 16;14(9):1163-70
references: 10894280
references: Acta Paediatr. 1992 Feb;81(2):133-6
references: 1381248
references: Br J Haematol. 2003 Oct;123(1):22-33
references: 14510939